B A C K G R O U N D
Severe anaemia and cerebral malaria complicate Plasmodium falciparum infection, and cause most of the 1-2 million deaths caused by malaria each year (WHO 1990) . In areas with stable and intense transmission of malaria, anaemia may cause more deaths than cerebral malaria (Slutsker 1994 , Snow 1994 ).
Blood transfusion is often given to patients with severe malarial anaemia, and can be important in preventing death in very ill patients (English 1996) . In other patients who are clinically stable, blood may be given simply on the basis of low haemoglobin, to prevent clinical deterioration. The other potential benefits are that it shortens recovery from anaemia, shortens hospital stay, reduces the length of follow up, and reduces the period in which patients are vulnerable as a result of their anaemic state (Bojang 1997a ).
There are risks in blood transfusion: it can cause circulatory overload, transfusion reactions, and occasionally, death (Ness 1990 , Garratty 1997 , Goodnough 1999 . There is also the risk of infection with HIV, hepatitis B or other pathogens (Greenberg 1988 , Sazama 1994 . Some experts recommend that patients with severe malarial anaemia who are otherwise clinically stable should be managed conservatively as haemoglobin has been shown to rise rapidly following antimalarial chemotherapy in a remarkable proportion of such cases (Pape 1989 , Holzer 1993 .
Conservative management corresponds with consensus guidelines for severe anaemia of any cause (ACP 1992 , WHO 1989 . The World Health Organization recommends that red cell transfusion is necessary only if the anaemia is associated with incipient or established cardiac failure (WHO 1989) . Similarly, the American College of Physicians has recommended that blood transfusion in acute or chronic anaemia should only be given in symptomatic patients who failed to respond to other suitable resuscitative measures (ACP 1992) . However some practice audit reports have shown that inappropriate blood transfusion is still common (Mozes 1989 , Jager 1990 , Ghali 1994 .
In developing countries, blood transfusion may be further complicated by inadequate supply of donor blood, trained personnel and other basic requirements for good quality care. The potentially harmful effects of blood may be increased in these resourcepoor settings since inadequate supervision of laboratory and clinical staff may increase the risk of incorrect cross matching, inadequate screening, poorly given transfusions and badly managed reactions.
The aim of this systematic review is to assess the benefits and harms of blood transfusion in severe malarial anaemia from randomised controlled trials. Since the balance of effects could vary depending on age and severity of illness, we intend to stratify the analysis by severity, and to consider sub-group analysis of children, adults and pregnant women.
O B J E C T I V E S
To evaluate the effect of routine blood transfusion in patients with malaria and severe anaemia on death and severe adverse events.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised and quasi-randomised controlled trials of routine blood transfusion.
Types of participants
Children or adults (irrespective of any inherited red blood cell disorders) with severe anaemia and confirmed malaria parasitaemia. Diagnosis of malaria was applied as a criterion for inclusion regardless of the species of malaria parasites. Definition of severe anaemia: Although the most widely cited definition of severe anaemia is haematocrit < 15%, the definition of severe anaemia in reviewed literature varied from haematocrit of 13% or less (Fullerton 1962 ) to < 20% (Hedberg 1993 . Haematocrit < 20% has been adopted as the definition for this review in order to avoid exclusion of many good trials on the basis of haematocrit cut-off points. Inclusion of participants with inherited red cell disorders: Indications other than severe anaemia are well recognised in patients with inherited red cell disorders, notably sickle cell anaemia. Patients with those specific indicators would be expected to be excluded from trials strictly designed to determine the effects of blood transfusion in severe malarial anaemia patients who are otherwise stable. It is also possible that some good trials may not consider these disorders as criteria for exclusion. This explanation justifies the inclusion of this category of participants in the review.
Types of interventions

Intervention
Blood transfusion.
Control
Conservative management.
Types of outcome measures Primary outcome
Death within two months.
Other outcomes
• Severe adverse events.
• Duration of stay in hospital.
• Re-admissions.
• Respiratory distress in the 1st week.
• Need for additional transfusion.
• Increase in haematocrit during follow-up.
• HIV and Hepatitis B status.
Search methods for identification of studies
We attempted to identify all relevant studies regardless of language or publication status (published, unpublished, in press, and in progress) . We used the following search terms for all trial registers and databases: blood transfusion, haemotherapy, anaemia and malaria. The search strategy was further enlarged to include two inherited red cell disorders (sickle cell anaemia and thalassaemia) which are commonly associated with severe anaemia in many malarious areas. The reviewers also drew on existing reviews of this topic, and checked the citations of all the trials identified by the above methods. The review panel and external referees, were asked to check the completeness of the search strategy, and to identify any additional unpublished, ongoing and planned trials.
Data collection and analysis
Selection of studies
The inclusion criteria were independently applied to all identified studies by the two reviewers, and when in doubt the opinion of the editor was sought.
Data extraction and management
Data were extracted from the selected trials using a standard form. Data retrieved included methods, types of participants, interventions and outcome. Unpublished data, and additional data for published studies, requested from individuals or organizations, were obtained on a standard form.
Assessment of risk of bias in included studies
Study quality was assessed using the standard methods of the Cochrane Infectious Diseases Group.
Data synthesis
Anaemia severity was defined as "very severe" for haematocrit (PCV) < 12%, and "moderately severe" for haematocrit = 12-19%. Presence of signs of cardiac failure in severe anaemia was stratified as "very severe" regardless of PCV. This definition is a consensus view based on published studies and personal communication with over twenty experts.
Comparison was between transfused participants and the nontransfused controls. Estimates of effect were assessed using Risk Ratio (RR) or Mean Difference (MD) with 95% Confidence Intervals. A fixed effects model was used for meta-analysis. Where analysis showed evidence of heterogeneity of effectiveness between studies, sub-group analysis was used to explore plausible explanations, including severity of anaemia, age, co-existing morbidity (especially sickle cell anaemia) and variations in the type, speed and mode of blood transfusion.
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies.
Eligibility
A total of 42 studies were identified but only two met the inclusion criteria (see 'Characteristics of included studies'). The main reasons for exclusion were non-randomisation of blood transfusion, non-inclusion of severe anaemia as a selection criterion and location outside malarious areas (see 'Characteristics of excluded studies').
Location
The included studies were conducted in The Gambia and Tanzania. A total of 230 children aged two months to nine years with severe anaemia were included in the two trials.The detail of the characteristics of each study is shown in the Table of included studies.
Study details
Participants -both studies excluded children with PCV < 12%, haemorrhage or features of congestive cardiac failure (eg respiratory distress and gallop rhythm). One study (Holzer 1993) also excluded patients with temperature > 38°C while the other (Bojang 1997a) excluded those with sickle cell disease or severe malnutrition. The PCV range of participants was 12-17% (Holzer 1993) and 12% to <15% (Bojang 1997a) respectively. This means that both trials exlcuded the "very severe" cases. Sickle cell anaemia patients were excluded from one trial (Bojang 1997a) while the other trial was unclear regarding the inclusion or exclusion of this category of patients. Intervention -A total number of 118 received blood transfusion while 112 did not. Both trials used whole blood for transfusion but the volume transfused was 15ml/kg in one (Bojang 1997a) and 20ml/kg in the other trial. Non-transfused participants received oral iron supplements in one study (Bojang 1997a) and none in the other trial. In Holzer 1993, all patients received treatment for malaria with chloroquine (25 mg/kg) followed by prophylaxis (5 mg/kg/week). In Bojang 1997a, a combination of chloroquine and sulfadoxinepyrimethamine was used, followed by chemoprophylaxis (weekly Maloprim -dapsone+pyrimethamine) by the 28th day of followup in randomly selected sub-groups of transfused (19) and nontransfused (16) participants.
Risk of bias in included studies
Both trials were randomised but the method of generation of allocation sequence was adequate in one (Holzer 1993) and unclear in the other. The adequacy of allocation concealment could not be determined in both trials. Investigators were not blinded probably due to the nature of the intervention. Studies were not analysed according to the intention-to-treat principle. Both trials recorded high percentage of loss to follow-up. In Holzer 1993, 16 (13.8%) participants were lost to follow-up by the 8th week (10 transfused and 6 non-transfused) but mortality data was ascertained in five of them (2 transfused and 3 non-transfused). In Bojang 1997a, 26 (22.8%) participants were lost to follow-up by the 8th week (11 transfused and 15 non-transfused). Five children in the transfusion group were not transfused becaused their PCV increased while they were waiting for blood to be provided. Both studies did not give clear indication of the sources of the blood used in the trials.
Effects of interventions Primary outcomes Death
Combining the two trials, there were fewer deaths among transfused participants (1/118) than non-transfused patients (3/112) but the numbers were small, and the result not statistically significant (Analysis 1.1).
Severe adverse events
Bojang 1997a reported convulsions (4 patients) and coma (3 patients) following transfusion but none in the non-transfused. Holzer 1993 reported chills and fever in one transfused participant who later died. Seven out of eight adverse events occured in one trial (Bojang 1997a), with only one event in the other. Results were not combined since the risk effect between the studies is so different ( Analysis 1.2). Number of deaths and severe adverse events were pooled. One participant (Holzer 1993) , who experienced an adverse event then later died, was counted only once in this analysis. The meta-analysis showed no significant difference in risk of either death or an adverse event between transfused and non-transfused participants (RR 2.54 95% CI 0.69 to 9.34, Analysis 1.3).
Other outcomes
Duration of stay in hospital
Bojang 1997a reported duration of stay in hospital, and this was significantly longer in the non-transfused group of participants (MD 1.88, 95% CI 2.41 to 1.35, Analysis 1.4). Holzer 1993 reported a higher rate of re-admission among the non-transfused (RR 0.23, 95% CI 0.03 to 2.03, Analysis 1.5) but did not report length of stay.
Respiratory distress in the first week
The risk of developing severe respiratory distress in the follow-up period was shown by one trial (Bojang 1997a) to be significantly higher among non-transfused participants (RR 0.04, 95% CI 0.00 to 0.70, Analysis 1.6). The other trial did not report this event but identified one case of bilateral pneumonia among the nontransfused.
Need for additional transfusion
See Analysis 1.7. One trial showed that more participants in the non-transfused group (10/56) than the transfused group (0/58) needed blood transfusion in addition to their primary allocation of the intervention. The criterion for additional transfusion was 'clinical assessment' in Holzer 1993, but not stated by Bojang 1997a. In the Bojang trial, 10 children from the non-transfused arm required additional transfusion because they developed respiratory distress, and in Holzer 1993 one child from the non-transfused arm was treated with quinine and blood was transfused, but the child died soon after transfusion.
Increase in haematocrit during follow-up
In both studies, mean haematocrit at baseline in the transfusion and non-transfusion groups were similar. The haematocrit by day 7 of follow-up reported by Bojang 1997a was significantly higher in transfused participants (MD 3.39, 95% CI 1.5 to 5.3, Analysis 1.8). By day 28, haematocrit was significantly higher in the non-transfused participants in one study (Bojang 1997a; MD 2.10, 95% CI 3.52 to 0.68, Analysis 1.9) and was not significantly different in the other trial (Holzer 1993; MD 0.90, 95% CI 1.55 to 3.35, Analysis 1.9). Day 56 haematocrit (Holzer 1993) showed no significant difference between transfused and non-transfused participants (MD 0.70, 95% CI -2.98 to 1.59, Analysis 1.10). The other trial did not report data on haematocrit by day 56.
Effect on Plasmodium parasitaemia
In the trial that compared blood transfusion with iron supplements (Bojang 1997a), there was no significant difference in the proportion of participants with parasitaemia on days 7 and 28 of follow-up (RR 0.97, 95% CI 0.06 to 15.06; same for both days, Analysis 1.11 and Analysis 1.12). This outcome was not pre-specified.
HIV and hepatitis B transmission
None of the trials reported the evaluation of these outcomes.
Other adverse events
No additional severe adverse events attributable to blood or the other drugs was recorded.
D I S C U S S I O N
These studies were small, and neither study appeared to conceal allocation. The small size means we cannot be sure whether early transfusion improves survival in children with moderate malaria associated with anaemia. Loss to follow up was >10%, which could also bias the results.
The trials did not evaluate the risk of HIV or hepatitis B virus transmission which would require longer term follow up. Clearly in centres where screening is routine this is less of a risk, but these are often fatal infections.
There was also lack of information on patients with sickle cell anaemia since these were excluded from one trial (Bojang 1997a) and inadequately reported in the other.
There is evidence from one trial that non-transfused children stayed longer in hospital than the transfused. Whether this is a result of arbitrary policies about haemoglobin level at discharge or some other clinical decision is not clear.
The mean value in haematocrit during follow-up was higher in transfused children during the first week but this did not persist. The non-transfused children had clearly higher mean haematocrit in one trial (Bojang 1997a) but lower mean haematocrit in the other trial by day 28. One of the trials (Bojang 1997a) gave iron supplements to the non-transfused while the other (Holzer 1993) gave none and this may explain the more rapid increase in the haematocrit in the former.
Blood transfusion is given for several other reasons than severe anaemia in clinical practice (Hebert 1997b , Goodnough 1999 . Many of these other indications have been the subject of good clinical trials (Koshy 1988 , Lorente 1993 , Vichinsky 1995 , Adams 1998 , Yu 1998 , Hebert 1999 . However, these important trials do not provide an answer to the question of what the effective and safe standards should be for the use of blood transfusion for severe anaemia in malarious areas. The geographical and epidemiological relevance of this research question lies in the fact that malaria which is the leading cause of severe anaemia in endemic communities can be cured in most cases and recovery from malarial anaemia is known to be rapid following successful chemotherapy (van den Hombergh 1996 , Pape 1989 , WHO 1989 .
The data were too limited to explore potential factors modifying effects. However, both studies were conducted in stable endemic malarious areas: the effects of malaria may be more severe in people with little immunity, so transfusion in these groups could potentially be of greater benefit.
We found no information was available on adults. Evidence in these groups are important, especially pregnant women who are also exposed to risk of significantly higher morbidity and mortality from malarial anaemia.
A U T H O R S ' C O N C L U S I O N S Implications for practice
In children living in malarious areas with severe anaemia and no respiratory distress, there is insufficient reliable information to know whether routine administration of blood does more good than harm.
Arguments that blood transfusion helps haematocrit recovery over the subsequent weeks is not supported by evidence from one trial.
Implications for research
Larger randomised trials of blood transfusion with death as the primary outcome would be useful. The trials could also evaluate as secondary outcomes: respiratory distress and subsequent need for blood (within the first week); adverse events; increase in haematocrit (up to the 2nd month); duration of hospital stay; re-admission rate; HIV and Hepatitis B virus status (within 3-6 months). A carefully conducted large trial is likely to under-estimate the risk of HIV/HBV transmission, since greater care might be taken to avoid these infections in a trial, compared with routine practice.
Some clinicians believe that it is unethical to conduct studies on children with PCV between 12% and 17%, and believe their clinical judgement is better. We maintain that the best way of assessing this policy is to conduct a randomised controlled trial.
The reviewed trials excluded children with PCV < 12% who did not have signs of heart failure thereby losing information on this category of patients. Subsequent trials should include such patients and make room for sub-group analysis if necessary. A multicentre trial, contributing data to an individual patient data analysis, would help to explore the various factors that might modify effects. Potential sources of heterogeneity are clinical status on admission, age, pregnancy, nutritional status, presence of sickle cell trait or various forms of thalassaemia, and endemicity of malaria. 
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